All In Biotech

Drug Trial Radar · NCT03578081

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial

Last checked: Nov 19, 2026Latest source record: Apr 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 690 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

690

Actual

Start

Nov 20, 2018

Primary completion

Nov 8, 2021

Study completion May 1, 2023

Sponsor

Lead sponsor
Alliance for Clinical Trials in OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Jul 5, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase III trial studies how well olanzapine with or without fosaprepitant work in preventing chemotherapy induced nausea and vomiting in cancer patients receiving chemotherapy that causes vomiting. Olanzapine and fosaprepitant dimeglumine may help control nausea and vomiting in patients during chemotherapy. Olanzapine is usually given in combination with other drugs, including fosaprepitant dimeglumine. It is not yet known if olanzapine when given with other drugs, is still effective without using fosaprepitant dimeglumine for controlling nausea and vomiting.

Conditions

  • Malignant Neoplasm

Interventions

  • Palonosetron HydrochlorideDrug

    Given IV

  • Ondansetron HydrochlorideDrug

    Given IV or PO

  • DexamethasoneDrug

    Given PO

  • Fosaprepitant DimeglumineDrug

    Given IV

  • OlanzapineDrug

    Given PO

  • PlaceboOther

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. No Nausea Rate Defined as a Response of 0 in the Nausea Item of Nausea and Vomiting Daily Diary/Questionnaire in the Overall (0-120 Hours), Acute (0-24 Hours), and Delayed (24-120 Hours) PeriodsTime frame: Up to 120 hours

Locations

566 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • Kingman Regional Medical Center

    Kingman, Arizona

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona

  • Mayo Clinic in Arizona

    Scottsdale, Arizona

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas

  • Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas

  • PCR Oncology

    Arroyo Grande, California

  • Epic Care-Dublin

    Dublin, California

  • Bay Area Breast Surgeons Inc

    Emeryville, California

  • Epic Care Partners in Cancer Care

    Emeryville, California

  • Tibor Rubin VA Medical Center

    Long Beach, California

  • Contra Costa Regional Medical Center

    Martinez, California

  • Alta Bates Summit Medical Center - Summit Campus

    Oakland, California

  • Bay Area Tumor Institute

    Oakland, California

  • Desert Regional Medical Center

    Palm Springs, California

  • Epic Care Cyberknife Center

    Walnut Creek, California

  • Rocky Mountain Cancer Centers-Aurora

    Aurora, Colorado

  • The Medical Center of Aurora

    Aurora, Colorado

  • Boulder Community Hospital

    Boulder, Colorado

  • Boulder Community Foothills Hospital

    Boulder, Colorado

  • Rocky Mountain Cancer Centers-Boulder

    Boulder, Colorado

  • Rocky Mountain Cancer Centers - Centennial

    Centennial, Colorado

  • Cancer Center of Colorado at Sloan's Lake

    Denver, Colorado

  • Denver Health Medical Center

    Denver, Colorado

  • National Jewish Health-Main Campus

    Denver, Colorado

  • The Women's Imaging Center

    Denver, Colorado

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • Presbyterian - Saint Lukes Medical Center - Health One

    Denver, Colorado

  • Rocky Mountain Cancer Centers-Midtown

    Denver, Colorado

  • SCL Health Saint Joseph Hospital

    Denver, Colorado

  • Rocky Mountain Cancer Centers-Rose

    Denver, Colorado

  • Rose Medical Center

    Denver, Colorado

  • Western Surgical Care

    Denver, Colorado

  • Mountain Blue Cancer Care Center - Swedish

    Englewood, Colorado

  • Swedish Medical Center

    Englewood, Colorado

  • National Jewish Health-Western Hematology Oncology

    Golden, Colorado

  • Saint Mary's Hospital and Regional Medical Center

    Grand Junction, Colorado

  • Grand Valley Oncology

    Grand Junction, Colorado

  • North Colorado Medical Center

    Greeley, Colorado

Showing 40 of 566 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.